Jagsonpal Pharmaceuticals Profit & Loss Annual

BSE: 507789 | NSE: JAGSNPHARM | ISIN: INE048B01027 | Sector: Major Drugs

675.60 +35.40 (5.53%)Updated : 25 Nov 2024

Interim Data

Annual Data

Fiscal Period	2024	2023	2022	2021
Period End Date	Mar 24	Mar 23	Mar 22	Mar 21
Revenue	208.70	236.71	217.58	187.95
Total Revenue	208.70	236.71	217.58	187.95
Costof Revenue Total	93.29	102.33	89.75	80.78
Gross Profit	115.42	134.39	127.83	107.17
Selling/ General/ Admin Expenses Total	48.49	99.29	101.76	53.98
Depreciation/ Amortization	1.66	1.18	1.53	1.09
Other Operating Expenses Total	43.86	-	-	34.11
Total Operating Expense	187.30	206.54	193.08	169.95
Operating Income	21.40	30.17	24.50	17.99
Interest Inc( Exp) Net- Non- Op Total	-8.14	32.98	19.04	-4.28
Other Net	9.28	0.98	0.15	4.31
Net Income Before Taxes	29.87	34.81	26.64	21.87
Provisionfor Income Taxes	7.41	8.09	7.79	4.81
Net Income After Taxes	22.46	26.72	18.86	17.06
Net Income Before Extra Items	22.46	26.72	18.86	17.06
Net Income	22.46	26.72	18.86	17.06
Income Availableto Com Excl Extra Ord	22.46	26.72	18.86	17.06
Income Availableto Com Incl Extra Ord	22.46	26.72	18.86	17.06
Diluted Net Income	22.46	26.72	18.86	17.06
Diluted Weighted Average Shares	2.66	2.62	2.62	2.62
Diluted EPS Excluding Extra Ord Items	8.46	10.20	7.20	6.51
DPS- Common Stock Primary Issue	5.00	5.00	4.00	1.00
Diluted Normalized EPS	8.46	11.19	7.19	6.51
Unusual Expense( Income)	-	3.75	0.04	-
Gain( Loss)on Saleof Assets	-	3.59	0.85	-